A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas
This study is testing two oral medications, AMXT 1501 and eflornithine (DFMO), combined together to fight hard-to-treat childhood cancers. Researchers want to find the safest dose and see how well this treatment combination works against aggressive tumors.
This trial is for patients who were 26 years old or younger at diagnosis and have specific types of rare brain tumors, bone cancers, or nerve cell tumors. Participants must also meet certain health and body size requirements to safely join.
Participants will take the study medications by mouth and closely work with the medical team to monitor safety and side effects. Doctors will regularly check how the tumors respond to the treatment and how well the body handles the drugs.
The study is currently recruiting patients and takes place at select medical centers in locations such as Alabama, Arkansas, and Connecticut. Your care team can help you find the most convenient location for your visits.
- 1Tests two oral medications combined to target stubborn childhood cancers
- 2Open to patients diagnosed at age 26 or younger with specific tumor types
- 3Currently recruiting participants at select locations across the United States
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.